Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Eli Lilly $4.5 Billion Notes Offering
Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and…
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the…
Sienna Biopharmaceuticals, Inc. $20 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by…
Alector, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of…
Aeglea BioTherapeutics, Inc. Common Stock and Pre-Funded Warrants Offering
Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre…
Revance Therapeutics, Inc. $115 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $115…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
Alnylam Pharmaceuticals, Inc. $387.5 Million Common Stock Offering
Davis Polk advised the sole book-running manager of a $387.5 million SEC-registered offering of 5,000,000 shares of common…
Bristol-Myers Squibb Acquires Celgene
Davis Polk is advising Morgan Stanley & Co. LLC, Evercore and Dyal Co. LLC as financial advisers to Bristol-Myers Squibb…
The Medicines Company $150 Million Convertible Notes Offering
Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150…